Jan Westerink
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jan Westerink has a total of 310 co-authors. Here are the top co-authors by number of shared publications:
- Frank L. J. Visseren
University Medical Center Utrecht
32 shared publications Yolanda van der Graaf
Julius Center for Health Sciences and Primary care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
10 shared publicationsHendrik M. Nathoe
Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands
8 shared publications- Gert Jan de Borst
Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, the Netherlands
5 shared publications Harold W. de Valk
Department of Internal Medicine, University Medical Center Utrecht, Utrecht, the Netherlands
5 shared publicationsL. Jaap Kappelle
Department of Neurology, University Medical Center Utrecht, Utrecht, The Netherlands
5 shared publications
Latest Publications
- Open Access
- 16 June 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e77429
Prevalence of and Risk Factors for Metabolic Syndrome, Vascular Damage, and Accelerated Aging (MetVasA) After Pediatric Hematopoietic Stem Cell Transplantation for Hematological Malignancy: Protocol for a Cross-Sectional Cohort Study
Background: Survivors of hematopoietic stem cell transplantation (HSCT) in childhood face a high risk of metabolic and cardiovascular disease as well as accelerated aging. Estimates of the prevalence of these severe late effects have varied widely because they have been based on small cohorts or mixed populations of patients that received transplantations for both malignant and nonmalignant diseases, and the co-occurrence of these late effects was not assessed. Therefore, the true burden of these complications in survivors of hematological malignancies remains unclear. Moreover, the role of potentially modifiable risk factors such as health behaviors and inflammation has not yet been determined. Objective: This study aims to determine the prevalence of metabolic syndrome (MetS), endothelial dysfunction (ED), and accelerated aging and their risk factors, including treatment-related factors, inflammation, and health behaviors, in a large representative cohort of Dutch survivors of HSCT in childhood. Additionally, the study will examine the co-occurrence of these late effects. Methods: This cross-sectional cohort study will combine 2 cohorts of survivors of HSCT in childhood for a hematological malignancy. The first cohort (cohort 1; n=102) consists of survivors who received transplantations before 2002 and were participants of the Dutch Childhood Cancer Survivor Study LATER 2 cohort, a nationwide cohort study focusing on late effects among long-term childhood cancer survivors. The second cohort will include survivors who received transplantations between 2002 and 2021 (cohort 2; projected n=120) and visited the late effects (LATER) outpatient clinic of the Princess Máxima Center between 2024 and 2026. Key outcomes will be the prevalence of MetS (≥3 of 5 clinical criteria), accelerated aging (3 of 5 biological and clinical criteria), and ED (assessed by endothelial peripheral arterial tonometry) and their co-occurrence. A broad range of potential and modifiable risk factors will be investigated, including treatment-related factors; transplant complications (eg, graft-versus-host disease); and health behaviors, including physical activity, dietary intake and status assessed with nutritional biomarkers, substance use, sun exposure, and relaxation. Results: Patient recruitment started in January 2024 and is estimated to last until June 2026. As of September 2025, a total of 77 participants have been included in the study. Conclusions: This study will provide insight into the prevalence of MetS, ED, and accelerated aging, as well as potentially modifiable risk factors, including those that have not been previously examined, among survivors of HSCT for hematological malignancies in childhood. The findings will inform surveillance guidelines and support the development of health behavioral and anti-inflammatory interventions to mitigate the risk of these severe late effects. International Registered Report Identifier (IRRID): DERR1-10.2196/77429
- 16 June 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e77429
Open AccessPrevalence of and Risk Factors for Metabolic Syndrome, Vascular Damage, and Accelerated Aging (MetVasA) After Pediatric Hematopoietic Stem Cell Transplantation for Hematological Malignancy: Protocol for a Cross-Sectional Cohort Study
Background: Survivors of hematopoietic stem cell transplantation (HSCT) in childhood face a high risk of metabolic and cardiovascular disease as well as accelerated aging. Estimates of the prevalence of these severe late effects have varied widely because they have been based on small cohorts or mixed populations of patients that received transplantations for both malignant and nonmalignant diseases, and the co-occurrence of these late effects was not assessed. Therefore, the true burden of these complications in survivors of hematological malignancies remains unclear. Moreover, the role of potentially modifiable risk factors such as health behaviors and inflammation has not yet been determined. Objective: This study aims to determine the prevalence of metabolic syndrome (MetS), endothelial dysfunction (ED), and accelerated aging and their risk factors, including treatment-related factors, inflammation, and health behaviors, in a large representative cohort of Dutch survivors of HSCT in childhood. Additionally, the study will examine the co-occurrence of these late effects. Methods: This cross-sectional cohort study will combine 2 cohorts of survivors of HSCT in childhood for a hematological malignancy. The first cohort (cohort 1; n=102) consists of survivors who received transplantations before 2002 and were participants of the Dutch Childhood Cancer Survivor Study LATER 2 cohort, a nationwide cohort study focusing on late effects among long-term childhood cancer survivors. The second cohort will include survivors who received transplantations between 2002 and 2021 (cohort 2; projected n=120) and visited the late effects (LATER) outpatient clinic of the Princess Máxima Center between 2024 and 2026. Key outcomes will be the prevalence of MetS (≥3 of 5 clinical criteria), accelerated aging (3 of 5 biological and clinical criteria), and ED (assessed by endothelial peripheral arterial tonometry) and their co-occurrence. A broad range of potential and modifiable risk factors will be investigated, including treatment-related factors; transplant complications (eg, graft-versus-host disease); and health behaviors, including physical activity, dietary intake and status assessed with nutritional biomarkers, substance use, sun exposure, and relaxation. Results: Patient recruitment started in January 2024 and is estimated to last until June 2026. As of September 2025, a total of 77 participants have been included in the study. Conclusions: This study will provide insight into the prevalence of MetS, ED, and accelerated aging, as well as potentially modifiable risk factors, including those that have not been previously examined, among survivors of HSCT for hematological malignancies in childhood. The findings will inform surveillance guidelines and support the development of health behavioral and anti-inflammatory interventions to mitigate the risk of these severe late effects. International Registered Report Identifier (IRRID): DERR1-10.2196/77429
- Open Access
- 14 February 2026
- Published by Elsevier in The American Journal of Medicine
- Vol. 139 (6) , 708-717.e5
Implications of 2023 ACR/EULAR classification criteria for antiphospholipid syndrome and current diagnostic and therapeutic insights: A Delphi consensus
- 14 February 2026
- Published by Elsevier in The American Journal of Medicine
- Vol. 139 (6) , 708-717.e5
Open AccessImplications of 2023 ACR/EULAR classification criteria for antiphospholipid syndrome and current diagnostic and therapeutic insights: A Delphi consensus
- Open Access
- 27 May 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (10) , 5287-5294
DISH as a marker for incident diabetes mellitus in cardiovascular disease patients
Objectives: DISH is a common incidental finding in medical imaging characterized by continuous vertebral ossification, which is associated with prevalent type 2 diabetes mellitus (T2DM). We hypothesized that incidental screen-detected DISH may be an actionable marker for incident diabetes screening and aimed to assess the absolute incidence rate (ratio) for T2DM in cardiovascular patients with and without DISH. Methods: Cardiovascular disease patients without diabetes (n = 3395) were included via the prospective Second Manifestation of ARTerial disease cohort. DISH was evaluated at baseline on chest radiographs using Resnick criteria. Incident T2DM was assessed by an adjudication committee. Adjusted incidence rate ratios (IRRs) and numbers needed to screen were calculated. Results: DISH was present in 263 (7.7%) patients. After a median follow-up of 11.1 years (IQR: 7.1–15.2), 317 patients developed T2DM. Patients with DISH had a higher incidence rate for T2DM compared with no-DISH patients (17.1 vs. 7.8 T2DM per 1000 person-years). DISH was associated with incident T2DM in multivariate analyses (IRR: 1.47; 95% CI: 1.03–2.06), with the highest IRR in the DISH group with the most extensive ossification (IRR: 2.01; 95% CI: 1.15–3.29). The number needed to screen for T2DM in patients with screen-detected DISH for 11.1 years was 7, similar to accepted risk markers overweight (n = 8), obesity (n = 5), hypertension (n = 9) and hyperlipidaemia (n = 13). Conclusions: DISH is associated with higher rates of incident T2DM in cardiovascular disease patients, independent of accepted risk markers. DISH could be used as an imaging marker to identify cardiovascular disease patients with an increased risk for subsequent T2DM.
- 27 May 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (10) , 5287-5294
Open AccessDISH as a marker for incident diabetes mellitus in cardiovascular disease patients
Objectives: DISH is a common incidental finding in medical imaging characterized by continuous vertebral ossification, which is associated with prevalent type 2 diabetes mellitus (T2DM). We hypothesized that incidental screen-detected DISH may be an actionable marker for incident diabetes screening and aimed to assess the absolute incidence rate (ratio) for T2DM in cardiovascular patients with and without DISH. Methods: Cardiovascular disease patients without diabetes (n = 3395) were included via the prospective Second Manifestation of ARTerial disease cohort. DISH was evaluated at baseline on chest radiographs using Resnick criteria. Incident T2DM was assessed by an adjudication committee. Adjusted incidence rate ratios (IRRs) and numbers needed to screen were calculated. Results: DISH was present in 263 (7.7%) patients. After a median follow-up of 11.1 years (IQR: 7.1–15.2), 317 patients developed T2DM. Patients with DISH had a higher incidence rate for T2DM compared with no-DISH patients (17.1 vs. 7.8 T2DM per 1000 person-years). DISH was associated with incident T2DM in multivariate analyses (IRR: 1.47; 95% CI: 1.03–2.06), with the highest IRR in the DISH group with the most extensive ossification (IRR: 2.01; 95% CI: 1.15–3.29). The number needed to screen for T2DM in patients with screen-detected DISH for 11.1 years was 7, similar to accepted risk markers overweight (n = 8), obesity (n = 5), hypertension (n = 9) and hyperlipidaemia (n = 13). Conclusions: DISH is associated with higher rates of incident T2DM in cardiovascular disease patients, independent of accepted risk markers. DISH could be used as an imaging marker to identify cardiovascular disease patients with an increased risk for subsequent T2DM.
- Open Access
- 15 May 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Prevalence of and Risk Factors for Metabolic Syndrome, Vascular Damage, and Accelerated Aging (MetVasA) After Pediatric Hematopoietic Stem Cell Transplantation for Hematological Malignancy: Protocol for a Cross-Sectional Cohort Study (Preprint)
BACKGROUND Survivors of hematopoietic stem cell transplantation (HSCT) in childhood face a high risk of metabolic and cardiovascular disease as well as accelerated aging. Estimates of the prevalence of these severe late effects have varied widely because they have been based on small cohorts or mixed populations of patients that received transplantations for both malignant and nonmalignant diseases, and the co-occurrence of these late effects was not assessed. Therefore, the true burden of these complications in survivors of hematological malignancies remains unclear. Moreover, the role of potentially modifiable risk factors such as health behaviors and inflammation has not yet been determined. OBJECTIVE This study aims to determine the prevalence of metabolic syndrome (MetS), endothelial dysfunction (ED), and accelerated aging and their risk factors, including treatment-related factors, inflammation, and health behaviors, in a large representative cohort of Dutch survivors of HSCT in childhood. Additionally, the study will examine the co-occurrence of these late effects. METHODS This cross-sectional cohort study will combine 2 cohorts of survivors of HSCT in childhood for a hematological malignancy. The first cohort (cohort 1; n=102) consists of survivors who received transplantations before 2002 and were participants of the Dutch Childhood Cancer Survivor Study LATER 2 cohort, a nationwide cohort study focusing on late effects among long-term childhood cancer survivors. The second cohort will include survivors who received transplantations between 2002 and 2021 (cohort 2; projected n=120) and visited the late effects (LATER) outpatient clinic of the Princess Máxima Center between 2024 and 2026. Key outcomes will be the prevalence of MetS (≥3 of 5 clinical criteria), accelerated aging (3 of 5 biological and clinical criteria), and ED (assessed by endothelial peripheral arterial tonometry) and their co-occurrence. A broad range of potential and modifiable risk factors will be investigated, including treatment-related factors; transplant complications (eg, graft-versus-host disease); and health behaviors, including physical activity, dietary intake and status assessed with nutritional biomarkers, substance use, sun exposure, and relaxation. RESULTS Patient recruitment started in January 2024 and is estimated to last until June 2026. As of September 2025, a total of 77 participants have been included in the study. CONCLUSIONS This study will provide insight into the prevalence of MetS, ED, and accelerated aging, as well as potentially modifiable risk factors, including those that have not been previously examined, among survivors of HSCT for hematological malignancies in childhood. The findings will inform surveillance guidelines and support the development of health behavioral and anti-inflammatory interventions to mitigate the risk of these severe late effects. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/77429
- 15 May 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessPrevalence of and Risk Factors for Metabolic Syndrome, Vascular Damage, and Accelerated Aging (MetVasA) After Pediatric Hematopoietic Stem Cell Transplantation for Hematological Malignancy: Protocol for a Cross-Sectional Cohort Study (Preprint)
BACKGROUND Survivors of hematopoietic stem cell transplantation (HSCT) in childhood face a high risk of metabolic and cardiovascular disease as well as accelerated aging. Estimates of the prevalence of these severe late effects have varied widely because they have been based on small cohorts or mixed populations of patients that received transplantations for both malignant and nonmalignant diseases, and the co-occurrence of these late effects was not assessed. Therefore, the true burden of these complications in survivors of hematological malignancies remains unclear. Moreover, the role of potentially modifiable risk factors such as health behaviors and inflammation has not yet been determined. OBJECTIVE This study aims to determine the prevalence of metabolic syndrome (MetS), endothelial dysfunction (ED), and accelerated aging and their risk factors, including treatment-related factors, inflammation, and health behaviors, in a large representative cohort of Dutch survivors of HSCT in childhood. Additionally, the study will examine the co-occurrence of these late effects. METHODS This cross-sectional cohort study will combine 2 cohorts of survivors of HSCT in childhood for a hematological malignancy. The first cohort (cohort 1; n=102) consists of survivors who received transplantations before 2002 and were participants of the Dutch Childhood Cancer Survivor Study LATER 2 cohort, a nationwide cohort study focusing on late effects among long-term childhood cancer survivors. The second cohort will include survivors who received transplantations between 2002 and 2021 (cohort 2; projected n=120) and visited the late effects (LATER) outpatient clinic of the Princess Máxima Center between 2024 and 2026. Key outcomes will be the prevalence of MetS (≥3 of 5 clinical criteria), accelerated aging (3 of 5 biological and clinical criteria), and ED (assessed by endothelial peripheral arterial tonometry) and their co-occurrence. A broad range of potential and modifiable risk factors will be investigated, including treatment-related factors; transplant complications (eg, graft-versus-host disease); and health behaviors, including physical activity, dietary intake and status assessed with nutritional biomarkers, substance use, sun exposure, and relaxation. RESULTS Patient recruitment started in January 2024 and is estimated to last until June 2026. As of September 2025, a total of 77 participants have been included in the study. CONCLUSIONS This study will provide insight into the prevalence of MetS, ED, and accelerated aging, as well as potentially modifiable risk factors, including those that have not been previously examined, among survivors of HSCT for hematological malignancies in childhood. The findings will inform surveillance guidelines and support the development of health behavioral and anti-inflammatory interventions to mitigate the risk of these severe late effects. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/77429
- Open Access
- 8 April 2024
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 31 (14) , 1671-1678
Development and validation of a lifetime prediction model for incident type 2 diabetes in patients with established cardiovascular disease: the CVD2DM model
Aims: Identifying patients with established cardiovascular disease (CVD) who are at high risk of type 2 diabetes (T2D) may allow for early interventions, reducing the development of T2D and associated morbidity. The aim of this study was to develop and externally validate the CVD2DM model to estimate the 10-year and lifetime risks of T2D in patients with established CVD. Methods and results: Sex-specific, competing risk-adjusted Cox proportional hazard models were derived in 19 281 participants with established CVD and without diabetes at baseline from the UK Biobank. The core model’s pre-specified predictors were age, current smoking, family history of diabetes mellitus, body mass index, systolic blood pressure, fasting plasma glucose, and HDL cholesterol. The extended model also included HbA1c. The model was externally validated in 3481 patients from the UCC-SMART study. During a median follow-up of 12.2 years (interquartile interval 11.3–13.1), 1628 participants with established CVD were diagnosed with T2D in the UK Biobank. External validation c-statistics were 0.79 [95% confidence interval (CI) 0.76–0.82] for the core model and 0.81 (95% CI 0.78–0.84) for the extended model. Calibration plots showed agreement between predicted and observed 10-year risk of T2D. Conclusion: The 10-year and lifetime risks of T2D can be estimated with the CVD2DM model in patients with established CVD, using readily available clinical predictors. The model would benefit from further validation across diverse ethnic groups to enhance its applicability. Informing patients about their T2D risk could motivate them further to adhere to a healthy lifestyle.
- 8 April 2024
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 31 (14) , 1671-1678
Open AccessDevelopment and validation of a lifetime prediction model for incident type 2 diabetes in patients with established cardiovascular disease: the CVD2DM model
Aims: Identifying patients with established cardiovascular disease (CVD) who are at high risk of type 2 diabetes (T2D) may allow for early interventions, reducing the development of T2D and associated morbidity. The aim of this study was to develop and externally validate the CVD2DM model to estimate the 10-year and lifetime risks of T2D in patients with established CVD. Methods and results: Sex-specific, competing risk-adjusted Cox proportional hazard models were derived in 19 281 participants with established CVD and without diabetes at baseline from the UK Biobank. The core model’s pre-specified predictors were age, current smoking, family history of diabetes mellitus, body mass index, systolic blood pressure, fasting plasma glucose, and HDL cholesterol. The extended model also included HbA1c. The model was externally validated in 3481 patients from the UCC-SMART study. During a median follow-up of 12.2 years (interquartile interval 11.3–13.1), 1628 participants with established CVD were diagnosed with T2D in the UK Biobank. External validation c-statistics were 0.79 [95% confidence interval (CI) 0.76–0.82] for the core model and 0.81 (95% CI 0.78–0.84) for the extended model. Calibration plots showed agreement between predicted and observed 10-year risk of T2D. Conclusion: The 10-year and lifetime risks of T2D can be estimated with the CVD2DM model in patients with established CVD, using readily available clinical predictors. The model would benefit from further validation across diverse ethnic groups to enhance its applicability. Informing patients about their T2D risk could motivate them further to adhere to a healthy lifestyle.
- Open Access
- 8 March 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (6) , 2229-2238
Lifetime and 10‐year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE‐T1D model
Aims: To develop and externally validate the LIFE‐T1D model for the estimation of lifetime and 10‐year risk of cardiovascular disease (CVD) in individuals with type 1 diabetes. Materials and Methods: A sex‐specific competing risk‐adjusted Cox proportional hazards model was derived in individuals with type 1 diabetes without prior CVD from the Swedish National Diabetes Register (NDR), using age as the time axis. Predictors included age at diabetes onset, smoking status, body mass index, systolic blood pressure, glycated haemoglobin level, estimated glomerular filtration rate, non‐high‐density lipoprotein cholesterol, albuminuria and retinopathy. The model was externally validated in the Danish Funen Diabetes Database (FDDB) and the UK Biobank. Results: During a median follow‐up of 11.8 years (interquartile interval 6.1–17.1 years), 4608 CVD events and 1316 non‐CVD deaths were observed in the NDR ( n = 39 756). The internal validation c‐statistic was 0.85 (95% confidence interval [CI] 0.84–0.85) and the external validation c‐statistics were 0.77 (95% CI 0.74–0.81) for the FDDB ( n = 2709) and 0.73 (95% CI 0.70–0.77) for the UK Biobank ( n = 1022). Predicted risks were consistent with the observed incidence in the derivation and both validation cohorts. Conclusions: The LIFE‐T1D model can estimate lifetime risk of CVD and CVD‐free life expectancy in individuals with type 1 diabetes without previous CVD. This model can facilitate individualized CVD prevention among individuals with type 1 diabetes. Validation in additional cohorts will improve future clinical implementation.
- 8 March 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (6) , 2229-2238
Open AccessLifetime and 10‐year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE‐T1D model
Aims: To develop and externally validate the LIFE‐T1D model for the estimation of lifetime and 10‐year risk of cardiovascular disease (CVD) in individuals with type 1 diabetes. Materials and Methods: A sex‐specific competing risk‐adjusted Cox proportional hazards model was derived in individuals with type 1 diabetes without prior CVD from the Swedish National Diabetes Register (NDR), using age as the time axis. Predictors included age at diabetes onset, smoking status, body mass index, systolic blood pressure, glycated haemoglobin level, estimated glomerular filtration rate, non‐high‐density lipoprotein cholesterol, albuminuria and retinopathy. The model was externally validated in the Danish Funen Diabetes Database (FDDB) and the UK Biobank. Results: During a median follow‐up of 11.8 years (interquartile interval 6.1–17.1 years), 4608 CVD events and 1316 non‐CVD deaths were observed in the NDR ( n = 39 756). The internal validation c‐statistic was 0.85 (95% confidence interval [CI] 0.84–0.85) and the external validation c‐statistics were 0.77 (95% CI 0.74–0.81) for the FDDB ( n = 2709) and 0.73 (95% CI 0.70–0.77) for the UK Biobank ( n = 1022). Predicted risks were consistent with the observed incidence in the derivation and both validation cohorts. Conclusions: The LIFE‐T1D model can estimate lifetime risk of CVD and CVD‐free life expectancy in individuals with type 1 diabetes without previous CVD. This model can facilitate individualized CVD prevention among individuals with type 1 diabetes. Validation in additional cohorts will improve future clinical implementation.
- 24 June 2023
- Published by Springer Nature in Huisarts en wetenschap
- Vol. 66 (7-8) , 21-24
Ervaringen met SGLT2-remmers
- 24 June 2023
- Published by Springer Nature in Huisarts en wetenschap
- Vol. 66 (7-8) , 21-24
Ervaringen met SGLT2-remmers
- Open Access
- 24 October 2022
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (2) , 435-443
Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study
Aim: To assess the potential gain in the number of life‐years free of a (recurrent) cardiovascular disease (CVD) event with optimal cardiovascular risk management (CVRM) and initiation of glucose‐lowering agents with proven cardiovascular benefit in people with type 2 diabetes (T2D). Materials and Methods: 9,416 individuals with T2D from the CAPTURE study, a non‐interventional, cross‐sectional, multinational study, were included. The diabetes lifetime‐perspective prediction model was used for calculating individual 10‐year and lifetime CVD risk. The distribution of preventive medication use was assessed according to predicted CVD risk and stratified for history of CVD. For the estimation of absolute individual benefit from lifelong preventive treatment, including optimal CVRM and the addition of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium‐glucose co‐transporter‐2 inhibitors (SGLT‐2is), the model was combined with treatment effects from current evidence. Results: GLP‐1 RA or SGLT‐2i use did not greatly differ between patients with and without CVD history, while use of blood pressure‐lowering medication, statins and aspirin was more frequent in patients with CVD. Mean (standard deviation [SD]) lifetime benefit from optimal CVRM was 3.9 (3.0) and 1.3 (1.9) years in patients with and without established CVD, respectively. Further addition of a GLP‐1 RA and an SGLT‐2i in patients with CVD gave an added mean (SD) lifetime benefit of 1.2 (0.6) years. Conclusions: Life‐years gained free of (recurrent) CVD by optimal CVRM and the addition of a GLP‐1 RA or aSGLT‐2i is dependent on baseline CVD status. These results aid individualizing prevention and promote shared decision‐making in patients with T2D.
- 24 October 2022
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (2) , 435-443
Open AccessCardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study
Aim: To assess the potential gain in the number of life‐years free of a (recurrent) cardiovascular disease (CVD) event with optimal cardiovascular risk management (CVRM) and initiation of glucose‐lowering agents with proven cardiovascular benefit in people with type 2 diabetes (T2D). Materials and Methods: 9,416 individuals with T2D from the CAPTURE study, a non‐interventional, cross‐sectional, multinational study, were included. The diabetes lifetime‐perspective prediction model was used for calculating individual 10‐year and lifetime CVD risk. The distribution of preventive medication use was assessed according to predicted CVD risk and stratified for history of CVD. For the estimation of absolute individual benefit from lifelong preventive treatment, including optimal CVRM and the addition of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium‐glucose co‐transporter‐2 inhibitors (SGLT‐2is), the model was combined with treatment effects from current evidence. Results: GLP‐1 RA or SGLT‐2i use did not greatly differ between patients with and without CVD history, while use of blood pressure‐lowering medication, statins and aspirin was more frequent in patients with CVD. Mean (standard deviation [SD]) lifetime benefit from optimal CVRM was 3.9 (3.0) and 1.3 (1.9) years in patients with and without established CVD, respectively. Further addition of a GLP‐1 RA and an SGLT‐2i in patients with CVD gave an added mean (SD) lifetime benefit of 1.2 (0.6) years. Conclusions: Life‐years gained free of (recurrent) CVD by optimal CVRM and the addition of a GLP‐1 RA or aSGLT‐2i is dependent on baseline CVD status. These results aid individualizing prevention and promote shared decision‐making in patients with T2D.
- Open Access
- 1 September 2022
- Published by Springer Nature in BMC Health Services Research
- Vol. 22 (1) , 1-12
The readiness of public primary health care (PUSKESMAS) for cardiovascular services in Makasar city, Indonesia
Backgrounds: The increasing burden of cardiovascular disease (CVD) has become a major challenge globally, including in Indonesia. Understanding the readiness of primary health care facilities is necessary to confront the challenge of providing access to quality CVD health care services. Our study aimed to provide information regarding readiness to deliver CVD health services in public primary health care namely Puskesmas.Methods: The study questionnaire was adapted from the World Health Organization (WHO) Service Availability and Readiness Assessment (SARA), modified based on the package of essentials for non-communicable disease (PEN) and the Indonesian Ministry of health regulation. Data were collected from all Puskesmas facilities (N = 47) located in Makassar city. We analysed relevant data following the WHO-SARA manual to assess the readiness of Puskesmas to deliver CVD services. Human resources, diagnostic capacity, supporting equipment, essential medication, infrastructure and guidelines, and ambulatory services domain were assessed based on the availability of each tracer item in a particular domain. The mean domain score was calculated based on the availability of tracer items within each domain. Furthermore, the means of all domains’ scores are expressed as an overall readiness index. Higher scores indicate greater readiness of Puskesmas to deliver CVD-related health care.Results: Puskesmas delivers health promotion, disease prevention, and prompt diagnosis for cardiovascular-related diseases, including hypertension, diabetes, coronary heart disease (CHD), and stroke. Meanwhile, basic treatments were observed in the majority of the Puskesmas. Long-term care for hypertension and diabetes patients and rehabilitation for CHD and stroke were only observed in a few Puskesmas. The readiness score of Puskesmas to deliver CVD health care ranged from 60 to 86 for. Furthermore, there were 11 Puskesmas (23.4%) with a score below 75, indicating a sub-optimal readiness for delivering CVD health services. A shortage of essential medicines and a low capacity for diagnostic testing were the most noticeable shortcomings leading to suboptimal readiness for high-quality CVD health services.Conclusion: Close cooperation with the government and other related stakeholders is required to tackle the identified shortcomings, especially the continuous monitoring of adequate supplies of medicines and diagnostic tools to achieve better CVD care for patients in Indonesia.
- 1 September 2022
- Published by Springer Nature in BMC Health Services Research
- Vol. 22 (1) , 1-12
Open AccessThe readiness of public primary health care (PUSKESMAS) for cardiovascular services in Makasar city, Indonesia
Backgrounds: The increasing burden of cardiovascular disease (CVD) has become a major challenge globally, including in Indonesia. Understanding the readiness of primary health care facilities is necessary to confront the challenge of providing access to quality CVD health care services. Our study aimed to provide information regarding readiness to deliver CVD health services in public primary health care namely Puskesmas.Methods: The study questionnaire was adapted from the World Health Organization (WHO) Service Availability and Readiness Assessment (SARA), modified based on the package of essentials for non-communicable disease (PEN) and the Indonesian Ministry of health regulation. Data were collected from all Puskesmas facilities (N = 47) located in Makassar city. We analysed relevant data following the WHO-SARA manual to assess the readiness of Puskesmas to deliver CVD services. Human resources, diagnostic capacity, supporting equipment, essential medication, infrastructure and guidelines, and ambulatory services domain were assessed based on the availability of each tracer item in a particular domain. The mean domain score was calculated based on the availability of tracer items within each domain. Furthermore, the means of all domains’ scores are expressed as an overall readiness index. Higher scores indicate greater readiness of Puskesmas to deliver CVD-related health care.Results: Puskesmas delivers health promotion, disease prevention, and prompt diagnosis for cardiovascular-related diseases, including hypertension, diabetes, coronary heart disease (CHD), and stroke. Meanwhile, basic treatments were observed in the majority of the Puskesmas. Long-term care for hypertension and diabetes patients and rehabilitation for CHD and stroke were only observed in a few Puskesmas. The readiness score of Puskesmas to deliver CVD health care ranged from 60 to 86 for. Furthermore, there were 11 Puskesmas (23.4%) with a score below 75, indicating a sub-optimal readiness for delivering CVD health services. A shortage of essential medicines and a low capacity for diagnostic testing were the most noticeable shortcomings leading to suboptimal readiness for high-quality CVD health services.Conclusion: Close cooperation with the government and other related stakeholders is required to tackle the identified shortcomings, especially the continuous monitoring of adequate supplies of medicines and diagnostic tools to achieve better CVD care for patients in Indonesia.
- Open Access
- 2 August 2022
- Published by Wolters Kluwer Health in Hypertension
- Vol. 79 (10) , 2328-2335
Higher Arm Versus Lower Arm Systolic Blood Pressure and Cardiovascular Outcomes: a Meta-Analysis of Individual Participant Data From the INTERPRESS-IPD Collaboration
BACKGROUND: Guidelines recommend measuring blood pressure (BP) in both arms, adopting the higher arm readings for diagnosis and management. Data to support this recommendation are lacking. We evaluated associations of higher and lower arm systolic BPs with diagnostic and treatment thresholds, and prognosis in hypertension, using data from the Inter-arm Blood Pressure Difference—Individual Participant Data Collaboration. METHODS: One-stage multivariable Cox regression models, stratified by study, were used to examine associations of higher or lower reading arm BPs with cardiovascular mortality, all-cause mortality, and cardiovascular events, in individual participant data meta-analyses pooled from 23 cohorts. Cardiovascular events were modelled for Framingham and atherosclerotic cardiovascular disease risk scores. Model fit was compared throughout using Akaike information criteria. Proportions reclassified across guideline recommended intervention thresholds were also compared. RESULTS: We analyzed 53 172 participants: mean age 60 years; 48% female. Higher arm BP, compared with lower arm, reclassified 12% of participants at either 130 or 140 mm Hg systolic BP thresholds (both P< 0.001). Higher arm BP models fitted better for all-cause mortality, cardiovascular mortality, and cardiovascular events (all P P <0.001) and reclassified 4.6% and 3.5% of participants respectively to higher risk categories compared with lower arm BPs). CONCLUSIONS: Using BP from higher instead of lower reading arms reclassified 12% of people over thresholds used to diagnose hypertension. All prediction models performed better when using the higher arm BP. Both arms should be measured for accurate diagnosis and management of hypertension. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: CRD42015031227.
- 2 August 2022
- Published by Wolters Kluwer Health in Hypertension
- Vol. 79 (10) , 2328-2335
Open AccessHigher Arm Versus Lower Arm Systolic Blood Pressure and Cardiovascular Outcomes: a Meta-Analysis of Individual Participant Data From the INTERPRESS-IPD Collaboration
BACKGROUND: Guidelines recommend measuring blood pressure (BP) in both arms, adopting the higher arm readings for diagnosis and management. Data to support this recommendation are lacking. We evaluated associations of higher and lower arm systolic BPs with diagnostic and treatment thresholds, and prognosis in hypertension, using data from the Inter-arm Blood Pressure Difference—Individual Participant Data Collaboration. METHODS: One-stage multivariable Cox regression models, stratified by study, were used to examine associations of higher or lower reading arm BPs with cardiovascular mortality, all-cause mortality, and cardiovascular events, in individual participant data meta-analyses pooled from 23 cohorts. Cardiovascular events were modelled for Framingham and atherosclerotic cardiovascular disease risk scores. Model fit was compared throughout using Akaike information criteria. Proportions reclassified across guideline recommended intervention thresholds were also compared. RESULTS: We analyzed 53 172 participants: mean age 60 years; 48% female. Higher arm BP, compared with lower arm, reclassified 12% of participants at either 130 or 140 mm Hg systolic BP thresholds (both P< 0.001). Higher arm BP models fitted better for all-cause mortality, cardiovascular mortality, and cardiovascular events (all P P <0.001) and reclassified 4.6% and 3.5% of participants respectively to higher risk categories compared with lower arm BPs). CONCLUSIONS: Using BP from higher instead of lower reading arms reclassified 12% of people over thresholds used to diagnose hypertension. All prediction models performed better when using the higher arm BP. Both arms should be measured for accurate diagnosis and management of hypertension. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: CRD42015031227.